|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
EBV type II latency tumors, such as Hodgkin lymphoma (HL), Non-Hodgkin lymphoma (NHL) and nasopharyngeal carcinoma, express a limited array of EBV antigens including Epstein-Barr nuclear antigen (EBNA)1, latent membrane protein (LMP)1, LMP2, and BamH1-A right frame 1 (BARF1).
|
30396848 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Materials and Methods In a dose escalation study, eight patients with Epstein Barr virus-positive Hodgkin lymphoma received two to 12 doses of between 2 × 10<sup>7</sup> and 1.5 × 10<sup>8</sup> cells/m<sup>2</sup> of DNRII-expressing T cells with specificity for the Epstein Barr virus-derived tumor antigens, latent membrane protein (LMP)-1 and LMP-2 (DNRII-LSTs).
|
29315015 |
2018 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Epstein-Barr virus (EBV)-encoded latent membrane proteins (LMP1 and LMP2) are consistently expressed by malignant Hodgkin Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD).
|
16276512 |
2005 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
|
15235393 |
2005 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
EBV-encoded latent membrane proteins, LMP1 and LMP2, are the only target antigens available for therapeutic augmentation of CTL responses in patients with HD and NPC.
|
12468425 |
2003 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based upon the success of using polyclonal, Epstein-Barr virus (EBV)-specific CTL lines for the prophylaxis and treatment of patients with post-transplant lymphoproliferative disease (PTLPD), there is now considerable incentive to develop CTL directed against the sub-dominant EBV antigens EBNA1, LMP1 and LMP2, which are expressed by the tumor cells of Hodgkin disease and nasopharyngeal carcinoma.
|
11241300 |
2001 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BARF1 expression was found in 6 of 7 nasopharyngeal carcinomas (NPC) but in 0 of 22 Hodgkin's disease (HD) cases, whereas LMP2 expression was found in 7 of 7 NPCs and in 17 of 22 HD cases.
|
9774558 |
1998 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, yet in HD the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 and LMP2 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen processing/presentation or in CTL function.
|
9746788 |
1998 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.
|
9259400 |
1997 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, nasopharyngeal carcinoma and Hodgkin's disease are predicted to express LMP2 proteins that contain conserved CTL target epitopes restricted through common HLA alleles; boosting responses to these epitopes could form the basis of a CTL-based therapy for these malignancies.
|
9120290 |
1997 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus (EBV)-positive Hodgkin's and Reed-Sternberg (HRS) cells express the virus-encoded latent membrane proteins LMP1 and LMP2 that could serve as rejection targets in Hodgkin's disease (HD).
|
7632957 |
1995 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assuming that LMP2-positive Reed-Sternberg cells would be sensitive to a CD8-positive cellular immune response, the hypothesis can be made that EBV-positive Hodgkin's disease should be more common in individuals not expressing HLA A2.
|
7515326 |
1994 |